The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Proteasome inhibitors-based combinations for elderly MM
María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the improvement in proteasome inhibitor-based combinations brought about for the management of newly diagnosed multiple myeloma (MM) in elderly patients. First used with a backbone of melphalan/prednisone, Dr Mateos says that various combinations are being used across the globe to treat this population of patients. Additionally, monoclonal antibodies, for example daratumumab, can be used on top of proteasome inhibitor-based combination of bortezomib, melphalan, prednisone (VMP). This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
